• Establish, recruit, manage and mentor the oncology discovery team of scientists and research associates.• Lead programs for several oncology targets using novel mRNA Epigenomic Therapeutics delivered via lipid nanoparticles, including Omega’s first clinical candidate, OTX-2002, for the treatment of patients with MYC-associated advanced solid tumors (with HCC-focused expansions), which is currently in a global Phase 1/2 clinical trial (July 2022).o Plan and execute robust mechanism of action and non-clinical pharmacology studies targeting oncogenic MYC using internal resources and Contract Research Organizations (CROs) to support and compose INTERACT (December 2020) and pre-IND Briefing Books (May 2021) ahead of the Investigational New Drug (IND) application (June 2022).o Write, review and updates to non-clinical pharmacology reports and modules for IND application and contribute to Information Requests (IR), the clinical protocol, annual updates to Investigational Brochure (IB) and Development Safety Update Report (DSUR).o Establish standard operating procedures through a quality management system (ZenQMS) for regulatory submissions of pharmacology documents.• Developing the translational research program for OTX-2002 clinical trial with application across the Omega platform.o Developing novel epigenetic assays for patient selection and pharmacodynamic biomarkers internally and in collaboration with CROs.o Determine time points and pharmacokinetic (PK)/pharmacodynamic (PD) samples to collect from patients for retrospective biomarker analysis.o Select vendors for clinical sample management/logistics and bioanalysis through consensus building across departments.• Prepare and present non-clinical data at major conferences (e.g., AACR, ASCO, and ESMO GI) and for journal articles.

o Initiated drug discovery programs for treating advanced age-related diseases such as osteoarthritis, sarcopenia and neurodegeneration (e.g. Parkinson’s, Huntington’s and Alzheimer’s diseases).• Established novel target pipeline research through Contract Research Organizations (CROs).

Head of Biology; Matrix management of a multi-disciplinary teamManagement of >40 academic and biotechnology external collaborations• Preparation and publishing of protocols and an investigator’s brochure including updates, amendments and contributions to annual Development Safety Update Report (DSUR).• Preparation of material and execution of site initiation visits for clinical trials• Initiation of and management of a clinical trial including tracking and understanding of efficacy and safety data• Prepared and presented preliminary clinical data at annual meetings for American Association of Cancer Research, American Society of Hematology, European Society of Medical Oncology, American Society of Clinical Oncology (ASCO), ASCO Genitourinary Symposium, ASCO Gastrointestinal Symposium.

Head of Biology• Determined time points and type of samples to collect from patients (e.g. pre- and post-treatment whole blood and plasma, leukocyte isolation, PAXgene tubes, bone marrow aspirates, fine needle biopsies, circulating tumor DNA isolation, CD138+ cell isolation, and circulating tumor cells) for prospective and retrospective biomarker determination.o Explored novel techniques for biomarker analysis (e.g. RNA and DNA sequencing, master regulators and promoter DNA methylation) using internal resources, collaborators, and CROs.o Determined PDn biomarkers using metabolite detection kits and mass spectrometry methods to measure nicotinamide dinucleotide and other metabolites from treated tissue culture cells, patient leukocytes and tumor biopsies from the Phase 1 trial of KPT-9274.o Designed and developed a Clinical Laboratory Improvement Amendments validated biomarker assay (e.g. quantitative methylation specific PCR and pyrosequencing of methylated DNA) for selection of patients with the likelihood to respond to KPT-9274. • Managed the Phase 1 clinical trial data including daily tracking of efficacy and safety to support and understand the translational research of XPO1 inhibitors and KPT-9274. • Participated in weekly calls with principal investigators (PIs) to share translational data and maintain site engagement.

Preparation and review of non-clinical reports and summary documents for INDs for the second generation XPO1 inhibitor, eltanexor and the PAK4/NAMPT inhibitor, KPT-9274.• Target identification using mass spectrometry proteomics and siRNA knockdown.• CLIA biomarker development to select patients. • Contribution to clinical poster presentations at major conferences.• Development and execution of cell-based and enzymatic assays.• Pharmacodynamic (PDn) biomarker development using all available technologies.• Design of target validation experiments using thermal stability, isothermal titration calorimetry, SPR, X-ray crystallography and in vitro kinase and binding assays.• Design of in vivo mouse studies using human xenografts and orthotopic models.• Design and management of ADME/PK studies in multiple animal species.

Developed small molecules against nuclear import/export machinery as a novel mechanism of cancer therapy. • Development of cell-based microscopy assay and analysis for XPO1 inhibitors• Predictive markers of response for selinexor• Preparation and review of non-clinical reports and summary documents for FDA submissions

o Performed independent research on tuberous sclerosis complex 1 (TSC1) gene product hamartin. o Examined TSC1 phosphorylation, interacting proteins, and localization during mitosis.o Performed Yeast Two-Hybrid library screen using TSC1 gene product to screen for protein-protein interactions.